Skip to main content
SpringerLink
Log in

Cancer du sein métastatique HER2 négatif nécessitant un traitement par chimiothérapie

  • Conference paper
Cancer du sein

  • 270 Accesses

Abstrait

La survenue de métastases marque un tournant évolutif dans la maladie. La médiane de survie des patientes à ce stade est de 24 à 36 mois, avec des variations importantes puisque certaines patientes meurent en quelques mois quand d’autres survivront plus de 10 ans (1, 2). Dans l’ensemble, il y a eu une amélioration faible mais indéniable de la prise en charge de ces patientes au cours des 20 dernières années. Ainsi, dans l’étude rétrospective réalisée à l’institut Gustave Roussy, au centre Léon Bérard et au centre Antoine Lacassagne sur 724 patientes traitées pour un cancer du sein métastatique d’emblée entre 1987 et 2000, les patientes traitées après 1993 ont une survie médiane améliorée de 5 mois par rapport à celles traitées entre 1987 et fin 1993 (29 mois contre 23). Cette amélioration est le fait de l’introduction, au cours des années 90, des anti-aromatases de troisième génération et de nouvelles drogues cytotoxiques comme les taxanes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Falkson G, Gelman RS, Leone L et al. (1990) Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 66: 1621–1629

    Article  PubMed  CAS  Google Scholar 

  2. Andre F, Slimane K, Bachelot T et al. (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22: 3302–3308

    Article  PubMed  Google Scholar 

  3. Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767

    PubMed  CAS  Google Scholar 

  4. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606

    PubMed  CAS  Google Scholar 

  5. Berry DA, Broadwater G, Klein JP et al. (2002) High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20: 743–750

    Article  PubMed  CAS  Google Scholar 

  6. Jassem J, Pienkowski T, Pluzanska A et al. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707–1715

    PubMed  CAS  Google Scholar 

  7. Nabholtz JM, Falkson C, Campos D et al. (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21: 968–975

    Article  PubMed  CAS  Google Scholar 

  8. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (El 193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  9. Seidman AD (2003) Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol 21: 577–579

    Article  PubMed  Google Scholar 

  10. Alba E, Martin M, Ramos M et al. (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22: 2587–2593

    Article  PubMed  CAS  Google Scholar 

  11. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  CAS  Google Scholar 

  12. Stadtmauer EA, O’Neill A, Goldstein LJ et al. (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069–1076

    Article  PubMed  CAS  Google Scholar 

  13. Biron P, Durand M, Roche H et al. (2002) High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. 2002 ASCO Annual Meeting, Abst # 167

    Google Scholar 

  14. Bachelot T, Gomez F, Biron P et al. (2002) A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. Br J Cancer 87: 1079–1085

    Article  PubMed  CAS  Google Scholar 

  15. Seidman AD (2003) Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol 21: 577–579

    Article  PubMed  Google Scholar 

  16. Bottomley A, Biganzoli L, Cufer T et al. (2004) Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 22: 2576–2586

    Article  PubMed  CAS  Google Scholar 

  17. Berry DA, Broadwater G, Klein JP et al. (2002) High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20: 743–750

    Article  PubMed  CAS  Google Scholar 

  18. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (El 193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  19. Seidman AD (2003) Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? J Clin Oncol 21: 577–579

    Article  PubMed  Google Scholar 

  20. Sledge GW Jr (2004) HERe-2 stay: the continuing importance of translational research in breast cancer. J Natl Cancer Inst 96: 725–727

    Article  PubMed  Google Scholar 

  21. Miller KD, Chap LI, Holmes FA et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799

    Article  PubMed  CAS  Google Scholar 

  22. Miller KD, Wang ML, Gralow JR et al. (2005) E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. 2005 ASCO Annual Meeting

    Google Scholar 

  23. Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460

    PubMed  CAS  Google Scholar 

  24. Carrick S, Parker S, Wilcken N (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane. Database Syst Rev CD003372

    Google Scholar 

  25. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (El 193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  26. Alba E, Martin M, Ramos M et al. (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22: 2587–2593

    Article  PubMed  CAS  Google Scholar 

  27. Jones D, Ghersi D, Wilcken N (2006) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane. Database Syst Rev 3: CD003368

    PubMed  CAS  Google Scholar 

  28. Farquhar C, Marjoribanks J, Basser R et al. (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane. Database Syst Rev CD003142

    Google Scholar 

  29. Seidman AD (2005) “Will Weekly Work”? Seems to Be So. J Clin Oncol 23: 5873–5874

    Article  PubMed  Google Scholar 

  30. Chan S, Friedrichs K, Noel D et al. (1997) A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 16: A540

    Google Scholar 

  31. Alba E, Ribelles N, Sevilla I et al. (2001) Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Res Treat 66: 33–39

    Article  PubMed  CAS  Google Scholar 

  32. Chan S, Friedrichs K, Noel D et al. (1999) Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer. J Clin Oncol 17: 2341

    PubMed  CAS  Google Scholar 

  33. Jones SE, Erban J, Overmoyer B et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542–5551

    Article  PubMed  CAS  Google Scholar 

  34. Sjostrom J, Blomqvist C, Mouridsen H et al. (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201

    Article  PubMed  CAS  Google Scholar 

  35. Bonneterre J, Roche H, Monnier A et al. (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210–1215

    Article  PubMed  CAS  Google Scholar 

  36. Nabholtz JM, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413–1424

    PubMed  CAS  Google Scholar 

  37. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. J Clin Oncol 20: 2812–2823

    Article  PubMed  CAS  Google Scholar 

  38. Ejlertsen B, Pfeiffer P, Pedersen D et al. (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527–531

    Article  PubMed  CAS  Google Scholar 

  39. Gregory RK, Powles TJ, Chang JC, Ashley S (1997) A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194–2197

    Article  PubMed  CAS  Google Scholar 

  40. Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137–144

    Article  PubMed  CAS  Google Scholar 

  41. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  42. Piccart-Gebhart M (2005) First results of the HERA trial. 2005 ASCO Annual Meeting

    Google Scholar 

  43. Romond EH, Perez EA, Bryant J et al. (2005) Doxorubicin and Cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG-N9831. 2005 ASCO Annual Meeting

    Google Scholar 

  44. Contesso G, Mouriesse H, Friedman S et al. (1987) The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 5: 1378–1386

    PubMed  CAS  Google Scholar 

  45. Galea MH, Blarney RW, Elston CE, Ellis IO ( 1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207–219

    Article  PubMed  CAS  Google Scholar 

  46. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302–2313

    Article  PubMed  CAS  Google Scholar 

  47. DeMichele A, Martin AM, Mick R et al. (2003) Interleukin-6-174G—>C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63: 8051–8056

    PubMed  CAS  Google Scholar 

  48. Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90: 8–11

    Article  PubMed  CAS  Google Scholar 

  49. Jin Q, Hemminki K, Enquist K et al. (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11: 3647–3653

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Léon Bérard, 28, rue Laennec, 69373, Lyon cedex 08

    I. Ray-Coquard & T. Bachelot

  2. Centre Léon Bérard Lyon, 28, rue Laënnec, 69008, Lyon

    J. -P. Guastalla

Authors
  1. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Bachelot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. -P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Ray-Coquard, I., Bachelot, T., Guastalla, J.P. (2007). Cancer du sein métastatique HER2 négatif nécessitant un traitement par chimiothérapie. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_23

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation